Given the high sensitivity and accuracy in detection of BRAF variation when analyzing a trace amount of tumor biopsies, this newer molecular assay could be implemented in most hospitals or clinical centers for timely identification and monitoring of BRAF variation status in tumors, thereby improving the treatment of patients with cancer harboring BRAF V600E. This evidence concerns the gene BRAF and cancer.